In the last trading session, 1,350,624 Galectin Therapeutics Inc. (NASDAQ:GALT) shares changed hands as the company’s beta touched 1.98. With the company’s per share price at $2.19 changed hands at -$0.04 or -0.02% during last session, the market valuation stood at $125.17 Million. GALT’s last price was a discount, traded about -75.8% off its 52-week high of $3.85. The share price had its 52-week low at $1.65, which suggests the last value was 24.66% up since then. When we look at Galectin Therapeutics Inc.’s average trading volume, we note the 10-day average is 191.65 Million shares, with the 3-month average coming to 303.76 Million.
Analysts gave the Galectin Therapeutics Inc. (GALT) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2. If we narrow down to specifics, the data shows that none out of 1 analysts rate the stock as a Sell, with a further none assigning it an Overweight rating. Of the remaining, none recommended GALT as a Hold, 1 felt it is a Buy and none rated the stock as Underweight. Galectin Therapeutics Inc.’s EPS for the current quarter is expected to be -$0.17.
Galectin Therapeutics Inc. (NASDAQ:GALT) trade information
Although GALT has turned red as seen at the end of in last trading. With action -1.79%, the performance over the past five days has been red. The jump to weekly highs of $2.86- on Wednesday, Apr 14 added 23.43% to the stock’s daily price. The company’s shares are showing year-to-date downside of -0.02%, with the 5-day performance at -0.16% in the red. However, in the 30-day time frame, Galectin Therapeutics Inc. (NASDAQ:GALT) is -0.08% down. Looking at the short shares, we see there were 4.77 Million shares sold at short interest cover period of 0.02 days.
The consensus price target for the stock as assigned by Wall Street analysts is $14, meaning bulls need an upside of 539.27% from its current market value. According to analyst projections, GALT’s forecast low is $14 with $14 as the target high. To hit the forecast high, the stock’s price needs a +539.27% upsurge from its current level, while the stock would need to tank 539.27% for it to hit the projected low.
Galectin Therapeutics Inc. (GALT) estimates and forecasts
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 13.9%. The 2021 estimates are for Galectin Therapeutics Inc. earnings to decrease by -7.1%, but the outlook for the next 5-year period is at 0% per year.
Galectin Therapeutics Inc. (NASDAQ:GALT)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 29.12% of Galectin Therapeutics Inc. shares while 17.81% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 25.12%. There are 98 institutions holding the Galectin Therapeutics Inc. stock share, with Blackrock Inc. the top institutional holder. As of Dec 30, 2020, the company held 4.55% of the shares, roughly 2.6 Million GALT shares worth $5.82 Million.
Vanguard Group, Inc. (The) holds the second largest percentage of outstanding shares, with 3.29% or 1.88 Million shares worth $4.21 Million as of Dec 30, 2020.
Among Mutual Funds, the top two as of Dec 30, 2020 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. With 1065160 shares estimated at $2.39 Million under it, the former controlled 1.86% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 1.81% of the shares, roughly 1.03 Million shares worth around $2.24 Million.